Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer have?
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer has 2,037 citations in the OpenAlex counts ScholarIQ stores.
When was Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer published?
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer has 2016 year in the ScholarIQ index.
What is the open-access status of Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer?
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer has bronze oa status in the ScholarIQ index.
What is the DOI of Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer?
The DOI for Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer is on the source record.
What is the PMID of Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer?
The PMID for Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer is on the source record.
What is the OpenAlex record for Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer?
The OpenAlex for Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer is on the source record.